- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06053645
Вес сердечно-сосудистых заболеваний
Тяжесть сердечно-сосудистых заболеваний: проспективное пилотное исследование взрослых с ожирением и сердечно-сосудистыми заболеваниями, оцененное в новой кардиометаболической клинике
The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.
Обзор исследования
Статус
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic in Rochester
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Patients referred to the cardiometabolic clinic at Mayo Clinic Hospital in Rochester, MN will be recruited for participation.
Описание
Inclusion Criteria:
- BMI ≥30 kg/m2
- At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
- Patients evaluated in the Cardiometabolic clinic
- Willingness to complete questionnaires/surveys
- Ability to complete monthly self-assessments at home
Exclusion Criteria:
- BMI <30 kg/m2
- Pregnancy or lactating women
- Hemodynamically unstable CVD
- Active malignancy
- Autoimmune or systemic inflammatory diseases
- Severe renal or hepatic failure
- Being considered unsafe to participate as determined by the study physician
- Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
- Patients with active psychosis, mania, or substance use disorders
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percent body weight loss
Временное ограничение: 12 months
|
Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss. |
12 months
|
|
Change in Body Mass Index (BMI)
Временное ограничение: Baseline, 12 months
|
Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703 |
Baseline, 12 months
|
|
Change in visceral adiposity distribution
Временное ограничение: Baseline, 12 months
|
Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA). |
Baseline, 12 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Blood Pressure
Временное ограничение: Baseline, 12 months
|
Measured in millimeters of mercury (mmHg) |
Baseline, 12 months
|
|
Change in point of care glucose
Временное ограничение: Baseline, 12 months
|
Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing. |
Baseline, 12 months
|
|
Change in quality of diet
Временное ограничение: Baseline, 12 months
|
Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)
Временное ограничение: Baseline, 12 months
|
Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)
Временное ограничение: Baseline, 12 months
|
Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire
Временное ограничение: Baseline, 12 months
|
Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress. |
Baseline, 12 months
|
|
Change in functional aerobic capacity (VO2 Max)
Временное ограничение: Baseline, 12 months
|
VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test |
Baseline, 12 months
|
|
Change in artificial intelligence electrocardiogram (AI-ECG) age
Временное ограничение: Baseline, 12 months
|
AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs). |
Baseline, 12 months
|
|
Change in E/e'
Временное ограничение: Baseline, 12 months
|
E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Peak Tricuspid Regurgitation (TR) Velocity
Временное ограничение: Baseline, 12 months
|
Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Right Atrial (RA) Pressure
Временное ограничение: Baseline, 12 months
|
RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in Left Atrial (LA) volume index
Временное ограничение: Baseline, 12 months
|
LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. |
Baseline, 12 months
|
|
Change in physical activity
Временное ограничение: Baseline, 12 months
|
Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in heart rate with detection of arrhythmia
Временное ограничение: Baseline, 12 months
|
Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in cardio fitness
Временное ограничение: Baseline, 12 months
|
Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in six-minute walk test
Временное ограничение: Baseline, 12 months
|
Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study. |
Baseline, 12 months
|
|
Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale
Временное ограничение: Baseline, 12 months
|
The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress. |
Baseline, 12 months
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Kyla Lara-Breitinger, M.D., Mayo Clinic
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 26-008806
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .